The impact of air pockets around the vaginal cylinder on vaginal vault brachytherapy by Onal, C. et al.
BJR © 2015 The Authors. Published by the British Institute of Radiology
Received:
18 October 2014
Revised:
9 December 2014
Accepted:
5 January 2015
doi: 10.1259/bjr.20140694
Cite this article as:
Onal C, Guler OC, Dolek Y. The impact of air pockets around the vaginal cylinder on vaginal vault brachytherapy. Br J Radiol 2015;88:20140694.
FULL PAPER
The impact of air pockets around the vaginal cylinder on
vaginal vault brachytherapy
C ONAL, MD, O C GULER, MD and Y DOLEK, MSci
Department of Radiation Oncology, Baskent University Faculty of Medicine, Adana, Turkey
Address correspondence to: Mr Cem Onal
E-mail: hcemonal@hotmail.com
Objective: To evaluate the incidence, size and predispos-
ing factors for air pockets around the vaginal cylinder and
their dosimetric effect on the vaginal mucosa.
Methods: We investigated 174 patients with endometrial
carcinoma treated with external radiotherapy (RT) and
brachytherapy (BRT) (101 patients, 58%) or BRT alone
(73 patients, 42%). The quantity, volume and dosimetric
impact of the air pockets surrounding the vaginal cylinder
were quantified. The proportions of patients with or
without air pockets during application were stratified
according to menopausal status, treatment modality and
interval between surgery and RT.
Results: Air pockets around the vaginal cylinder were
seen in 75 patients (43%), while 99 patients (57%) had no
air pockets. Only 11 patients (6.3%) received less than the
prescribed dose (average 93.9% of prescribed dose;
range, 79.0–99.2%). Air pockets were significantly fewer
in pre-menopausal patients or in patients treated with the
combination of external RT and BRT than in post-
menopausal patients or patients treated with BRT alone.
A significant correlation existed between the mucosal
displacement of the air gap and the ratio of the measured
dose at the surface of the air gap and prescribed dose
(Pearson r520.775; p,0.001).
Conclusion: Air pockets were still a frequent problem
during vaginal vault BRT, especially in post-menopausal
patients or in patients treated with BRT alone, which
may potentially cause dose reductions at the vaginal
mucosa.
Advances in knowledge: Air pockets around the vaginal
cylinder remain a significant problem, which may poten-
tially cause dose reduction in the target volume.
The primary treatment of choice in localized endometrial
cancer is surgery. Adjuvant radiotherapy (RT) is recom-
mended in intermediate- and high-risk patients in order to
diminish disease recurrence. RT can be in the form of
external RT (ERT) with vaginal vault brachytherapy (BRT)
or BRT only, depending on the risk factors and stage of
disease.
The purpose of vaginal vault BRT is to eradicate a micro-
scopic tumour at the lymphatics located in the vaginal
vault. It was demonstrated that .90% of lymphatics lie
within 2–3mm from the surface of stretched mucosa.1 For
this reason, in order to deliver adequate doses to the
submucosal lymphatics, the vaginal cylinder must be in
direct contact with the vaginal surface, as recommended by
the American Brachytherapy Society (ABS).2 The Group
Europee´n de Curiethe´rapie and the European Society for
Radiotherapy & Oncology (GEC-ESTRO) guidance3 is to
prescribe vaginal BRT to 5mm from the applicator surface
with a 2-mm tolerance. The most commonly used appli-
cator for vaginal vault high-dose-rate BRT is a segmented
cylinder.4 However, during application, air gaps may be
observed, which may potentially cause underdosage of the
vaginal mucosa.
Cameron et al5 found that 18 of 25 patients (72%) had air
gaps .2mm in the cranial part of the vagina, with the
median number of air pockets per patient being 1 (range,
0–5). Richardson et al6 reported that 20 of 25 patients
(80%) had at least 1 air pocket in the upper vagina. In
another study, Humphrey et al7 demonstrated .2mm air
gaps in 11/103 patients, while repositioning or use of
a larger cylinder reduced air gaps in 7/103 patients. How-
ever, in all of these studies, applicators of different sizes
were used with a limited number of patients and con-
flicting results have been reported.
In Baskent University Department of Radiation Oncology,
Adana, Turkey, we prefer using cylinders with the largest
diameter for reducing air gaps during vaginal vault BRT.
The purpose of this study was to evaluate the incidence,
size and dosimetric effects of these air pockets. In addition,
the predisposing factors for the development of air gaps
were analysed.
METHODS AND MATERIALS
Patients
The study population consisted of 174 consecutive patients with
pathologically proven endometrial carcinoma treated with post-
operative RT between January 2012 and May 2014. The BRT plans
and patient data were retrospectively analysed. Protocol approval
was obtained from the institutional review board for this study.
Before vaginal cylinder insertion, each patient had a detailed
pelvic examination, and the vaginal vault size was determined
upon examination and the vaginal cylinder with the largest di-
ameter that each patient could tolerate was inserted. The range of
cylinders in use varied in diameter between 3.0 and 3.5 cm. After
insertion of the cylinder to the top of the vagina, the applicator
was fixed with a universal applicator-clamping device (Varian®;
Varian Medical Systems, Palo Alto, CA), which was underneath
the patient. The length of the cylinder protruding outside the
vagina was noted to ensure accurate repositioning for subsequent
insertions. All subsequent treatments used the same diameter
and length of the cylinder. Moreover, before each BRT ses-
sion, the applicator was checked with fluoroscopy to confirm
that the positioning was the same for each treatment.
A CT scan with 2.5-mm slice thickness through the pelvis was
performed at the first BRT application in line with departmental
policy. All CTslices were transferred, via a hospital network, to the
treatment planning system (Brachyvision™ v. 8.1; Varian Medical
Systems). The dose was prescribed to a 5-mm depth for the 3- to
5-cm cranial part of the vagina.8 Patients were treated with an
iridium-192 high-dose afterloader (Varisource®; Varian Medical
Systems). The dose prescribed was 4Gy for three fractions in
patients treated with ERT and BRT, and 5Gy for five fractions for
patients treated with BRT only. 35 patients (20%) were treated
with a 3.0-cm diameter cylinder, and 139 patients (80%) were
treated with a 3.5-cm diameter cylinder.
Dosimetric analysis
The air pockets in the upper 3–5 cm of the vagina were con-
toured in the axial plane by a single investigator to minimize the
risk of interobserver variation, and the volumes were calculated
by the treatment planning system. The average number of air
pockets, average air pocket volume and maximum displacement
of the vaginal mucosa were recorded. The relative RT dose at the
point of maximum air gap measured by the treatment planning
system was recorded for all air gaps both at the surface and at
5mm from the surface of the cylinder and vaginal mucosa by
a single investigator (Figure 1). The ratio between the vaginal
mucosa displaced by the air pocket and the prescribed dose was
also recorded. The doses were calculated using the Task Group
43 formalism.9
Statistical analysis
Statistical analysis was performed using SPSS® v. 20.0 (SPSS
Inc., Chicago, IL), software. Time to ERT and BRT was cal-
culated as the time between surgery and initiation of ERT or
BRT. The proportions of patients with or without air pockets
during application were stratified by menopausal status,
treatment modality and the interval between surgery and RT. A
multiple linear regression model was used to identify in-
dependent predictors of air pockets around the vaginal cylin-
der. The x2 test or Fisher’s exact test, where appropriate, was
used to compare these proportions in different groups. The
correlation between the dose ratio and mucosal height and
their significance were calculated using the Pearson correlation
test. A p-value of ,0.05 was considered to be statistically
significant.
RESULTS
Patient characteristics
The median age of the patient cohort was 60 years (range,
27–81 years). Patient characteristics are summarized in Table 1.
Most of the patients (86%) were post-menopausal, and the
most commonly used vaginal cylinder (86%) was 3.5 cm in
diameter. 101 patients (58%) were treated with ERT and BRT,
while 73 patients (42%) were treated with BRT alone. Average
times between surgery and the initiation of ERT and BRT were
35 days (range, 5–334 days) and 67 days (range, 12–370 days),
respectively.
Figure 1. (a) Axial CT images of the vagina with a cylinder inserted demonstrating a small air pocket and (b) point dose calculation of
the dose to the vaginal mucosa, where the prescribed dose was 4Gy per fraction. The distance was measured from the surface of
the cylinder to the point of maximum displacement by a single observer. The dose was then determined at that point and compared
with the prescribed dose.
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Air pocket characteristics
Air pockets around the vaginal cylinder were seen in 75
patients (43%), while 99 patients (57%) had no air pockets.
36 patients (48%) had 1 air pocket, 27 patients (36%) and
12 patients (16%) had 2 and 3 air pockets, respectively. The air
pockets were located in the apical part of the cylinder in
30 patients (40%) and in the lateral sides of the cylinder in
29 patients (39%), while 16 patients (21%) had air pockets
located both at the apex and lateral sides of the cylinder.
The mean average distance of the mucosa displaced by air
pockets was 3.6mm (range, 1.8–8.8mm), and the average vol-
ume of air pockets was 0.31 cm3 (range, 0.04–2.93 cm3). Out of
174 patients, 68 (39%) had air pockets that displaced the vaginal
mucosa away from the surface of the cylinder by a distance of
$2mm. As demonstrated in Table 2, air pockets were signifi-
cantly less in pre-menopausal patients or in patients treated with
ERT and BRT than in post-menopausal patients or in patients
treated with BRT alone. Menopausal status (p5 0.006 and
r5 0.191) and treatment strategy (p5 0.02 and r5 0.154) were
independent contributors to the incidence of air pockets. Age,
the interval between surgery and ERT or BRT, and vaginal cyl-
inder diameter had no significant impact on the incidence of air
pockets.
Dosimetric effects of air pockets
The mean dose measured at the surface of the air gap was
6.13Gy (range, 3.23–11.13Gy). The dose ratio between the
vaginal mucosa displaced by the air pocket and the dose pre-
scribed was 1.41 (range, 0.79–2.25). Over the air gaps, the dose
that the mucosa received at 0.5 cm was on average 90.4% (range,
81.7–99.3%) of that expected in the absence of air gaps. There
was a significant correlation between the mucosal displacement
Table 1. Patient characteristics
Parameters n %
Stage
IA 43 25
IB 52 30
II 26 15
IIIA 22 13
IIIB 3 2
IIIC 28 16
Menopausal status
Pre-menopausal 25 14
Post-menopausal 149 86
Cylinder diameter
3.0 cm 25 14
3.5 cm 149 86
Fraction dose
4Gy 84 48
5Gy 90 52
Table 2. Factors affecting the presence of air pockets around the vaginal cylinder
Factors
Air pockets around vaginal cylinder
Present, n (%) Absent, n (%) p-value
Age (years), median (range) 60 (39–81) 59 (37–80) 0.85
Menopausal status
Pre-menopausal 5 (3) 20 (11) 0.02
Post-menopausal 70 (40) 79 (45)
Treatment modality
BRT alone 38 (22) 35 (20) 0.04
ERT1BRT 37 (21) 64 (37)
Time between surgery and ERT
,21 days 9 (9) 13 (13) 0.63
$21 days 28 (28) 51 (50)
Time between surgery and BRT
,21 days 8 (5) 67 (39) 0.48
$21 days 12 (7) 87 (50)
Vaginal cylinder diameter
3.0 cm 11 (6) 14 (8) 0.55
3.5 cm 64 (37) 85 (49)
BRT, brachytherapy; ERT, external radiotherapy.
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of the air gap and the ratio of the measured dose at the surface of
the air gap and prescribed dose (Pearson r520.775; p, 0.001)
(Figure 2). Only 11 patients (6.3%) with air gaps received less
radiation, an average of 93.9% of the prescribed dose (range,
79.0–99.2%).
The height of the air gap was significantly less in patients with
the 3.5-cm vaginal cylinder application than with the 3.0-cm
application (3.236 0.96mm vs 3.886 0.15mm; p5 0.03).
However, the mean dose measured at the surface of the air gaps
(6.276 1.10Gy vs 6.126 1.44Gy; p5 0.63) and the ratio of the
measured and prescribed doses (1.516 0.23 vs 1.406 0.29;
p5 0.23) were not significantly different between the 3.0- and
3.5-cm vaginal cylinders.
DISCUSSION
In the present study, we investigated the incidence and predis-
posing factors for air pockets around the vaginal cylinder during
vaginal vault BRT. In addition, we analysed the dosimetric effects
of the air gaps. In this study, air pockets were seen in 75 of 174
patients (43%), and the average number of air pockets ranged
from 1–3 per patient. However, only 11 patients (6.3%) received
less than the prescribed doses, with an average of 93.9% (range,
79.0–99.2%). Furthermore, we demonstrated that air pockets
were less frequent in pre-menopausal patients and in patients
treated with post-operative ERT and BRT.
The results of randomized trials for patients with intermediate-
risk endometrial carcinoma suggested that most (75%) locore-
gional recurrence was located in the vagina; thus, vaginal vault
BRT may be most effective for patients with intermediate- and
high-risk features in order to obtain local control with fewer side
effects compared with ERT and better quality of life.10 Data from
retrospective studies that used vaginal BRT alone for Stage I
mainly low-risk endometrial carcinoma (EC) showed 5-year rates
of vaginal relapse of 0–5%.11,12 Final results of the post-operative
radiation therapy for endometrial carcinoma (PORTEC)-2 trial
showed vaginal BRT to be highly effective in preventing vaginal
relapse. At median follow-up of 45 months, the estimated 5-year
rates of vaginal recurrence were 1.8% for BRT and 1.6% for ERT
(p5 0.74).10 In view of the efficacy of vaginal BRTwith fewer side
effects and better quality of life, in many countries, BRT alone has
become the standard of care for patients with endometrial cancer
with intermediate- to high-risk features.
The results from the PORTEC trial found that the rate of vaginal
relapse without RT is approximately 10%, with a vaginal vault
relapse of 6.4%.13 One possible cause of vaginal relapse is that
the vaginal mucosa does not receive the prescribed dose because
of the presence of air gaps. In a study by Cameron et al,5 18 of 25
(72%) patients had an average of 1 air gap, with a mean average
area of the air gap of 0.20 cm2 (range, 0.02–1.65 cm2). This
resulted in a mean average of 0.86% of the vaginal surface being
displaced from the surface of the cylinder. Richardson et al6 also
reported that 20 of 25 patients (80%) had $1 air pocket present
in the upper vagina in at least 1 of 6 treatment fractions.
The average total pocket volume was 0.34 cm3 (range,
0.01–1.32 cm3), and the average distance that the mucosa was
displaced was 3.7mm (range, 1.3–8.0mm) with 88.8% of the
vaginal mucosa displaced away from the cylinder surface by
$2mm. Humphrey et al7 found that 38 out of 103 patients
(37%) had $1 air gap within the target volume, while air gaps
Figure 2. Regression plots of the mucosa elevated by the air gaps around the vaginal cylinder vs the ratio of the dose measured at
the tip of the air gap to the prescribed dose [Pearson correlation coefficient (r)520.775; p,0.001].
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$2mm were seen in only 11 out of 103 patients. In this present
study, we found that 75 patients (43%) had $1 air gap with
a mean volume of 0.31 cm3 (range, 0.04–2.93 cm3) and an av-
erage distance of mucosa displacement of 3.6mm (range,
1.8–8.8mm) with 38.9% of the vaginal mucosa displaced away
from the surface of the cylinder by $2mm. The incidence of air
gaps was lower and similar between our study and that of
Humphrey et al,7 because in these studies, the vaginal cylinder
with the largest diameter ($3.0 cm) was used more frequently
than in other studies (Table 3). Another important finding was
that the incidence of vaginal mucosa displaced away from the
surface of the cylinder by $2mm was the highest in patients for
whom a smaller diameter cylinder was used compared with
other studies. We also analysed the difference in the height of the
air gap and found that the air gap height was significantly less in
patients with the 3.5-cm vaginal cylinder application than with
the 3.0-cm application. Therefore, we prefer using the cylinder
with the largest diameter based on the patient and target ge-
ometry after detailed gynaecological examination before cylinder
insertion, in order to ensure close mucosal apposition as rec-
ommended by the ABS.2
The dosimetric effect of air gaps around the vaginal cylinder has
not been well described. Richardson et al6 reported a 27%
(range, 9–58%) dose reduction to the vaginal mucosa at the air
pocket. However, the entire vaginal mucosal dose was not
reported. Cameron et al5 found that the dose at the mucosa over
the air gaps received at 0.5 cm was on average 86.7% (range,
54.7–97.3%) of that which it would have received if there was no
air gap. However, the dose at 0.5 cm of the whole vaginal mucosa
within the target volume was 99.6% (range, 96–100%) of that
prescribed. In the present study, although we found a significant
correlation between the mucosal displacement of the air gap and
the ratio of the measured dose at the surface of the air gap and
prescribed dose, only 11 patients (6.3%) had less than the pre-
scribed dose, which was still 93.9% (range, 79.0–99.2%).
ERT and/or vaginal BRT may cause shortening of the vagina
and fibrosis as a late reaction, whereas vaginal mucositis and
swelling might be seen acutely.14,15 In patients treated with
ERT, vaginal mucosal swelling and mucositis start during
treatment because of dilatation of mucosal vessels causing
oedema. Therefore, the vaginal cylinder could potentially cover
the whole mucosal surface, with less air gaps observed, as seen
in our study. Other factors including age and menopausal
status were also found to be significant for developing vaginal
mucositis in patients treated with ERT and vaginal BRT.14,16
Thus, such factors may be important to consider because the
vaginal mucosa of older, post-menopausal females becomes
thin, is replaced by connective tissue and loses its vasculature,
so the vaginal cylinder could not contact the whole vaginal
mucosa, when compared with the vaginal mucosa of younger,
pre-menopausal females, as observed in our study.
The present study has several limitations. The retrospective
nature of our study is the first limitation. Secondly, we only
performed a CT scan to investigate the air gaps present on the
first fraction of BRT. Most patients received three to five frac-
tions of BRT. The location of air gaps might have been different
at each treatment, further diluting their overall effect.6 Thirdly,
the dose required to eradicate microscopic metastases is un-
known. It is unclear whether an even lower dose would be
equally effective for low- or intermediate-risk patients. Hence,
even if there are air gaps, the dose to the raised vagina may still
be sufficient to eradicate micrometastases. If this is true, and if
the air gaps can be prevented, it may be possible that an even
lower dose of RT will be effective. Finally, although air pockets
were seen frequently, ,1% of patients received less than the
prescribed dose, which may have only a minor impact clinically.
However, this study is important for demonstrating the in-
cidence, predisposing factors and dosimetric effects of air gaps
around vaginal cylinder vaginal vault BRT using a higher patient
number than did previous studies.
CONCLUSION
To the best of our knowledge, this is the first study to evaluate
the incidence, predisposing factors and dosimetric effects of air
gaps during vaginal vault BRT. Although we used the largest
cylinders that the patient could tolerate in this study, air pockets
were still a frequent problem during vaginal vault BRT, especially
in post-menopausal patients or in patients treated with BRT
alone, which may potentially cause dose reductions at the vag-
inal mucosa. Since most centres prefer vaginal vault BRT alone
in high- to intermediate-risk patients, dose reductions caused by
air gaps may potentially allow local recurrence.
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Table 3. The studies evaluating the incidence of air gaps according to cylinder diameter
Study
Patient
number
Incidence of air gaps
(%)
Cylinder diameter (%) Mucosal elevation by
$2mm (%),3.0 cm 3.0 cm 3.5 cm
Cameron
et al5
25 72 44 36 20 32
Richardson
et al6
25 80 96 4 0 72
Humphrey
et al7
103 37 17 54 30 11
Present study 174 43 0 14 86 39
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